LRRK2 is a member of the protein kinase superfamily. It contains 12 LRR’s (leucine-rich repeats). It may play a role in the phosphorylation of proteins central to Parkinson disease. Phosphorylates PRDX3. May also have GTPase activity. Interacts with PARK2. Interacts with PRDX3. Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminergic areas. Defects in LRRK2 are the cause of Parkinson disease type 8 (PARK8). A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.

**IMMUNOGEN**

Synthetic peptide derived from the human LRRK2 protein

Immunohistochemical staining of normal human kidney tissue using LRRK2 antibody (Cat. No. X2733P) at 10 µg/ml and detected using anti-Rabbit HRP secondary antibody and visualized using DAB substrate and hematoxylin counterstain.
**POSITIVE CONTROL/TISSUE EXPRESSION**

Human kidney tissue

**COMMENTS**

Antibody can be used for immunohistochemistry (5-10 µg/ml). Optimal concentration should be evaluated by serial dilutions.

**PURIFICATION**

Antigen Immunoaffinity Purification

**SHIP CONDITIONS**

Ship at ambient temperature, freeze upon arrival

**STORAGE CUSTOMER**

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

**STABILITY**

Products are stable for one year from purchase when stored properly

**REFERENCES**


3. Alegre-Abarrategui, J., et al. 'LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson’s disease.' 2008, 34, 272-283

**PRODUCT SPECIFIC REFERENCES**